Loading...
01/11 13:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a decrease in revenue and net product sales, coupled with a significant net loss, despite cost reduction efforts. The Q&A session shows management's inability to provide clear guidance, particularly concerning regulatory interactions and vaccine developments. No share repurchase program is in place, and the market may react negatively to the weak financial performance and unclear future strategies. The absence of positive catalysts, like new partnerships or strong guidance, further supports a negative sentiment.
Q1 Revenue $108 million, a decrease of 35% year-over-year due to lower vaccination rates reflecting the transition of COVID into routine seasonal vaccination patterns.
Net Product Sales $86 million, primarily driven by COVID vaccine sales, with the US accounting for about a third of total sales.
Cost of Sales $90 million, a decrease of $6 million year-over-year due to lower sales volume.
R&D Expenses $856 million, a 19% decrease year-over-year driven by lower clinical development spend across respiratory programs.
SG&A Expenses $212 million, down 23% year-over-year due to broad-based cost reductions.
Net Loss $1 billion, an improvement of $204 million compared to a $1.2 billion loss in Q1 2024.
Loss Per Share $2.52, an improvement from a loss of $3.07 in the prior year period.
Cash and Investments $8.4 billion, down from $9.5 billion at the end of Q4, primarily driven by the operating loss for the quarter.
Projected R&D Expenses for 2025 Approximately $4.1 billion, reflecting continued investment in late-stage pipeline while maintaining financial discipline.
Projected SG&A Expenses for 2025 Approximately $1.1 billion, reflecting a continued focus on efficiency.
Projected Capital Expenditures for 2025 Approximately $400 million.
Projected Cash and Investments by end of 2025 Approximately $6 billion.
GAAP Operating Expense Forecast for 2026 Reduced from $5.9 billion to a range of $5.4 billion to $5.7 billion.
Projected Cash Cost for 2026 Approximately $4.7 billion at the midpoint of the range.
Projected GAAP Expenses for 2027 Between $4.7 billion and $5 billion.
Projected Cash Cost for 2027 Approximately $4.2 billion at the midpoint of the range.
Total Reduction in Annual GAAP Expenses from 2023 to 2027 Over $6 billion, representing a 55% reduction from $11 billion annually in 2023 to $5 billion or less in 2027.
New Product Approvals: mRESVIA received approvals in Australia, Taiwan, the UK, and Switzerland, in addition to previous approvals in the US, EU, and Canada.
Pipeline Expansion: Expansion of oncology portfolio with Checkpoint medicine and ongoing development of multiple vaccines including next-gen COVID, RSV, and flu plus COVID combination vaccines.
Regulatory Filings: Filed for regulatory approvals for three programs: next-gen COVID vaccine (mRNA-1283), RSV vaccine (mRNA-1345), and flu plus COVID combination vaccine (mRNA-1083).
Market Expansion: Awarded a tender opportunity for COVID vaccine business in Europe, enhancing market presence.
Sales Growth Potential: Targeting a total addressable market of over $30 billion with anticipated product approvals.
Cost Reduction: Achieved a 19% reduction in combined R&D, SG&A expenses year-over-year.
Financial Discipline: Third consecutive quarter of double-digit year-over-year declines in combined R&D and SG&A expenses.
Strategic Focus: Prioritizing sales of approved products and late-stage pipeline to drive growth and diversification.
Cost Efficiency Goals: Targeting a cash cost of $4.2 billion by 2027, aiming for cash breakeven.
Financial Performance Risks: Moderna reported a net loss of $1 billion for Q1 2025, reflecting the highly seasonal nature of its respiratory vaccine business and lower vaccination rates compared to the previous year.
Regulatory Approval Risks: The timeline for regulatory approvals of several products, including the flu plus COVID combination vaccine, has been extended due to the need for additional efficacy data, potentially delaying revenue generation.
Market Competition Risks: The company faces competitive pressures in the respiratory vaccine market, particularly with the transition of COVID vaccines into routine seasonal vaccination patterns, which may impact sales.
Supply Chain Challenges: While global tariffs have not significantly impacted Moderna, the company anticipates increased costs associated with the launch of new manufacturing sites in Australia, Canada, and the UK.
Economic Factors: The wide range of revenue guidance for 2025 reflects uncertainties in vaccination rates and the competitive market environment, which could affect overall financial performance.
R&D Investment Risks: Despite cost reductions, R&D expenses remain high, and the company is dependent on successful outcomes from ongoing clinical trials to justify continued investment.
Strategic Priority 1: Drive Sales of Approved Products, focusing on Spikevax and mRESVIA vaccines to enhance competitive positioning in the respiratory vaccine market.
Strategic Priority 2: Focus on late-stage pipeline to drive sales growth and diversification, targeting up to 10 product approvals with a total addressable market of over $30 billion.
Strategic Priority 3: Deliver cost efficiency across the entire business, with a commitment to further streamline operations and achieve cash breakeven target by 2025.
Cost Reduction Initiatives: Announced plans to achieve an additional $1.4 billion to $1.7 billion in cost reductions by 2027, with a total reduction of over $6 billion planned from 2023 to 2027.
2025 Revenue Guidance: Total revenue expected to be in the range of $1.5 billion to $2.5 billion, with first half sales of approximately $0.2 billion.
2025 Cost of Sales: Projected to be approximately $1.2 billion, reflecting improvements in manufacturing efficiency.
2025 R&D Expenses: Anticipated to be approximately $4.1 billion, maintaining investment in late-stage pipeline.
2025 SG&A Expenses: Expected to be approximately $1.1 billion, reflecting continued focus on efficiency.
2025 Capital Expenditures: Projected to be approximately $400 million.
2026 GAAP Operating Expense Guidance: Reduced from $5.9 billion to a range of $5.4 billion to $5.7 billion.
2027 GAAP Operating Expense Guidance: Projected to be between $4.7 billion and $5 billion.
2025 Cash and Investments: Expected to end 2025 with approximately $6 billion in cash and investments.
Share Repurchase Program: None
The earnings call summary and Q&A reveal concerns about declining vaccination rates, reduced revenue projections, and unclear guidance on future large deals. Despite cost reduction plans and strategic partnerships, the market may react negatively to the reduced revenue guidance and lack of detailed future growth projections. The negative sentiment is reinforced by declining COVID vaccine demand and the cautious outlook on new product launches. These factors suggest a likely negative stock price movement in the short term.
The earnings call suggests a positive outlook with strong financial metrics, ongoing product development, and strategic cost-cutting measures. The company is optimistic about its pipeline and regulatory interactions, despite some uncertainties in demand. The focus on partnerships and expansion in oncology and vaccines indicates growth potential. No significant negative trends were highlighted, and management's cautious optimism suggests a positive sentiment. However, the lack of specific guidance on some aspects prevents a stronger positive rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
